Oslo, March 13, 2024 Observe Medical released on March 13, 2024, its results for the full year and second half of 2023.
Business update
The strategic acquisition of trademarks and intellectual property rights for the UnoMeter™ portfolio from Convatec, coupled with the CE certification of UnoMeter™ 500, marked 2023 as a transformative year for Observe Medical. These milestones laid a strong groundwork for the company’s commercial growth.
In a year of commercial milestones, Observe Medical achieved growth and market expansion in 2023. We launched and delivered our first UnoMeter™ Abdo-Pressure and UnoMeter™ 500 products, demonstrating our capacity to meet market demand. Also, we expanded our distribution network to cover more than 20 countries, accounting for a substantial portion of historic Convatec sales territories.
Financial highlights
In the second half of 2023 (H2 2023), operating revenues increased to 16.1 MNOK, demonstrating an 8.6 MNOK improvement year-over-year (YoY). For the full year 2023 (FY 2023), revenues climbed to 27.9 MNOK, reflecting an 8.4 MNOK increase YoY.
Gross profit in H2 2023 increased, reaching 5.0 MNOK, up by 4.6 MNOK YoY. The FY 2023 gross profit was 9.3 MNOK, showing a solid increase of 4.1 MNOK YoY.
Despite the negative EBITDA figures, there has been a noticeable improvement. H2 2023’s EBITDA was -14.9 MNOK, which is a positive change of 12.3 MNOK compared to H2 2022. The FY 2023 EBITDA also improved by 10.8 MNOK YoY.
The net result shows a reduction in losses, with H2 2023 posting a loss of 25.159 MNOK, which is an 8.469 MNOK improvement over H2 2022. The FY 2023 net loss of 60.354 MNOK is also an improvement of 9.553 MNOK over FY 2022.
As announced on December 12, 2023, the Company completed a rights issue raising a total of 35.7 MNOK, which included 21.5 MNOK in cash contributions.
